Professional Marketing briefs: Biogen Idec, inVentiv Health, Abbott and Gilead Sciences

Share this content:

Biogen Idec's Tony Kingsley was promoted to run global commercial operations. Kingsley, was previously SVP US commercial operations, with responsibility for marketing, sales, market access, patient services, training and sales ops.

InVentiv Health said its Selling Solutions business will give outsourced sales operations support to pharma company Santarus, as well as recruiting and sales force automation services for the Santarus' prescription diabetes products.

Abbott put aside $1.5 billion for settlement of charges that it marketed epilepsy drug Depakote off label, the Chicago Tribune reported. An ex-rep whistleblower in the case alleges that sales trainees were first told not to market drugs off label, then told by an experienced rep to ignore that order and push the drug for an unapproved use—treatment of agitation associated with dementia.

Gilead Sciences licensed Tibotec's single-tablet combo of Prezista and Gilead's Emtriva for HIV. Under the deal, Gilead will lead formulation, manufacturing, registration and, if approved, distribution and commercialization globally, while Tibotec will have the right to co-detail the combo in certain major markets.
Share this content:
Scroll down to see the next article